Pharsight

Eucrisa generic

Eucrisa is a medicinal ointment owned by Anacor Pharms Inc. and primarily used for treating mild to moderate atopic dermatitis. The active ingredient in Eucrisa is crisaborole. This drug first entered the market on December 14, 2016.

When will Eucrisa generic be available?

The generic versions of Eucrisa could hit the market post-July 20, 2030. This estimate is based on the drug's patent details, particularly the US8168614 and its extension, US8168614*PED, which are set to expire on January 20, 2030, and July 20, 2030, respectively.

Eucrisa uses

Eucrisa ointment is employed in the treatment of mild to moderate atopic dermatitis, a common skin condition characterized by itchy, red, and inflamed skin. The drug's efficacy comes from its active ingredient, crisaborole, an anti-inflammatory agent.

Eucrisa patent expiration

Eucrisa is protected by 8 patents. The final patent, US8168614*PED, is slated to expire on July 20, 2030. For more information regarding the potential availability of Eucrisa generic, see below. Below are the details of the patents:

Eucrisa dosage

Want to ask something?